Terapia Hormonal e Hipertensão em Mulheres na Pós-Menopausa: Resultados do Estudo Longitudinal de Saúde do Adulto (ELSA-Brasil)

Ferreira-Campos, Luana; Gabrielli, Lígia; Almeida, Maria da Conceição Chagas de; Aquino, Estela Maria L; Matos, Sheila Maria Alvim; Griep, Rosane Härter; Aras, Roque

doi:10.36660/abc.20210218

Cited by 7 publications

(3 citation statements)

References 28 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 66 Furthermore, a study from Brazil showed that the use of MHT was associated with a lower risk for hypertension. 67 However, these were cross-sectional studies and the use of MHT in these studies was low (12.5%). 66 …”

Section: Discussionmentioning

confidence: 96%

“…In a large cross-sectional study across 11 Latin American countries, the Collaborative Group for Research of the Climacteric in Latin America (REDLINC) showed that the current use of menopausal hormone therapy (MHT) was associated with reduced risk of MetS 66 . Furthermore, a study from Brazil showed that the use of MHT was associated with a lower risk for hypertension 67 . However, these were cross-sectional studies, and the use of MHT in these studies was low (12.5%) 66 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The association of menopause with cardiometabolic disease risk factors in low- and middle-income countries: a systematic review and meta-analyses

Chikwati,

Chikowore,

Mahyoodeen

et al. 2023

Menopause

View full text Add to dashboard Cite

Importance Menopause is an integral part of women's health, and studies in high-income countries have shown an increase in cardiometabolic disease (CMD) risk factors in postmenopausal compared with premenopausal women. However, to date, no study has combined and assessed such studies across low- and middle-income countries. This would better inform early monitoring and intervention strategies for reducing CMD risk factor levels in midlife women in these regions. Objective This study aimed to evaluate evidence from the literature on differences in CMD risk factors between premenopausal and postmenopausal midlife women living in low- and middle-income countries. Evidence Review A systematic review with meta-analysis of original articles of all study designs from the databases PubMed, PubMed Central, Scopus, and ISI Web of Science was conducted from conception until April 24, 2023. Studies that met the inclusion criteria were included in the analysis. Quality assessment of the articles was done using the Newcastle-Ottawa Scale, adapted for each study design. The study protocol was registered with the International Prospective Register of Systematic Reviews and adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis. For the meta-analysis, fixed-effects models were used to pool the odds ratios (OR), as measures of association. Findings Our search identified 4,849 relevant articles: 44 for the systematic review and 16 for the meta-analysis, in accordance with our inclusion criteria. Compared with premenopausal women, the postmenopausal stage was associated with metabolic syndrome (OR, 1.18 [95% CI, 1.11-1.27]), high waist-to-hip ratio (OR, 1.22 [95% CI, 1.12-1.32]), hypertension (OR, 1.10 [95% CI, 1.04-1.16]), elevated triglycerides (OR, 1.16 [95% CI, 1.11-1.21]), and elevated plasma glucose (OR, 1.21 [95% CI, 1.15-1.28]). Conclusions and Relevance This study confirmed that CMD risk factors are present at higher levels in postmenopausal than premenopausal women. This demonstrates an urgent need for public health policies that focus on early monitoring and interventions targeted at reducing CMD risk and related adverse outcomes in midlife women in these nations.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

The association of menopause with cardiometabolic disease risk factors in low- and middle-income countries: a systematic review and meta-analyses

Chikwati,

Chikowore,

Mahyoodeen

et al. 2023

Menopause

View full text Add to dashboard Cite

show abstract

“…During this phase, women experiencing menopause-related symptoms may opt for hormone therapy (HT) to control moderate-to-severe vasomotor symptoms 3 . However, menopausal HT, which includes a wide variety of hormonal compounds and administration routes, still harbors uncertainties regarding its effects on blood pressure and its association with hypertension in postmenopausal women 4-8 …”

mentioning

confidence: 99%

Effect of hormone therapy on blood pressure and hypertension in postmenopausal women: a systematic review and meta-analysis

Ferreira Campos,

de Andrade Costa,

Domingues Feitosa

et al. 2024

Menopause

View full text Add to dashboard Cite

Importance Menopausal hormone therapy (HT) includes a wide variety of hormonal compounds, and its effect on blood pressure is still uncertain. Objective The aim of this study was to assess evidence regarding the effect of HT on blood pressure in postmenopausal women and its association with arterial hypertension. Evidence Review This systematic review and meta-analysis included randomized clinical trials and prospective observational studies. Systolic blood pressure (SBP), diastolic blood pressure (DBP), and the incidence of hypertension were assessed. All stages were independently performed by two reviewers. For blood pressure outcome, standardized mean differences (SMD) and 95% confidence intervals (95% CI) were calculated as effect measures. Heterogeneity was assessed using the I 2 statistic. The results are presented based on the HT type. The incidence of hypertension was compared using descriptive analyses. Findings Eleven studies were included with 81,041 women evaluated, of which 29,812 used HT. The meta-analysis, conducted with 8 studies and 1,718 women, showed an increase in SBP with the use of oral conjugated equine estrogens plus progestogen (SMD = 0.60 mm Hg, 95% CI = 0.19 to 1.01). However, oral or transdermal use of estradiol plus progestogen (SMD = −2.00 mm Hg, 95% CI = −7.26 to 3.27), estradiol alone, and tibolone did not show any significant effect. No significant effect on DBP was observed for any formulation. Women who used oral estrogen plus progestogen had a higher risk of incident hypertension than those who never used it. Conclusions and Relevance The effect of HT on blood pressure is influenced by the formulation used, especially the type of estrogen. The combined formulations of conjugated equine estrogens plus progestogen increased SBP and the risk of hypertension, which was not observed among estradiol plus progestogen, estradiol alone, and tibolone users.

show abstract

Photobiomodulation for Blood Pressure and Heart Rate Reduction in Mastectomized Women on Hormone Blockers: A Randomized Controlled Trial

Pacheco,

Molena,

Veiga

2024

Photobiomodulation, Photomedicine, and Laser Surgery

View full text Add to dashboard Cite

Terapia Hormonal e Hipertensão em Mulheres na Pós-Menopausa: Resultados do Estudo Longitudinal de Saúde do Adulto (ELSA-Brasil)

Cited by 7 publications

References 28 publications

The association of menopause with cardiometabolic disease risk factors in low- and middle-income countries: a systematic review and meta-analyses

The association of menopause with cardiometabolic disease risk factors in low- and middle-income countries: a systematic review and meta-analyses

Effect of hormone therapy on blood pressure and hypertension in postmenopausal women: a systematic review and meta-analysis

Photobiomodulation for Blood Pressure and Heart Rate Reduction in Mastectomized Women on Hormone Blockers: A Randomized Controlled Trial

Contact Info

Product

Resources

About